The determinants of pharmaceutical research and development expenditures

Journal of Evolutionary Economics

Volumn 10, Issue 1-2, 2000, Pages 201-215

  Grabowski, Henry ^a   Vernon, John ^a  

^a DUKE UNIVERSITY   (United States)

Author keywords

Cash flow; Expected returns; Innovation; Pharmaceuticals; R D

Indexed keywords

EID: 0034406123     PISSN: 09369937     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001910050012     Document Type: Article

References (27)

1. Baily MN (1972) Research and development costs and returns: the U.S. pharmaceutical industry. Journal of Political Economy 80: 70-85
2. Congressional Budget Office (1994) How health care reform affects pharmaceutical research and development. U.S. Congress, Washington
3. Cutler D, McClellan M, Newhouse J (1997) The costs and benefits of intensive treatment for cardiovascular disease. AEI/Brookings Institution, Conference on Measuring the Prices of Medical Treatments
4. Ellison SF, Cockburn I, Grilliches Z and Hausman J (1997) Characteristics of demand for pharmaceutical products: An examination of four cephalosporins. RAND Journal of Economics 28: 426-446
5. Geweke JF, Weisbrod BA (1981) Some economic consequences of technological advance in medical care: the case of a new drug. In: Helms RB (ed) Drugs and health. AEI Press, Washington
6. Grabowski HG (1968) The determinants of industrial research and development: a study of the chemical, drug and petroleum industries. Journal of Political Economy 76: 292-306
7. Grabowski HG, Mueller DC (1972) Managerial and stockholder welfare models of firm expenditures. Review of Economics and Statistics 54: 9-24
8. Grabowski HG, Vernon JM (1981) The determinants of R & D expenditures. In: Helms RB (ed) Drugs and health. AEI Press, Washington
9. Grabowski HG, Vernon JM (1990) A new look at the returns and risks to pharmaceutical R & D. Management Science 36: 804-821
10. Grabowski HG, Vernon JM (1994) Returns to R & D on New Drug Introductions in the 1980s. Journal of Health Economics 13: 383-406
11. Grabowski HG, Vernon JM (1997) The search for new vaccines: the effects of the Vaccines for Children Program. AEI Press, Washington
12. Green DG (1998) Is price regulation necessary? A summary of arguments. Pharmaco-economics 14, Supp.1: 137-142
13. Hall BH (1992) Investment and research and development at the firm level: does the source of financing matter. Working Paper no. 4096, NBER, Cambridge, Mass, June
14. Henderson R, Cockburn I (1996) Scale, scope and spillovers: The determinants of research productivity in drug discovery. RAND Journal of Economics 27: 32-59
15. Hubbard RG (1998) Capital-market imperfections and investment. Journal of Economic Literature 36: 193-225
16. Lichtenberg FR (1998) Pharmaceutical innovation as a process of creative destruction. Working Paper, Columbia University
17. Office of Technology Assessment (1993) Pharmaceutical R & D: Costs, risks and rewards. Congress of the United States, Washington
18. Pharmacy Times (1976) Compilation of new drugs: 1940 through 1975
19. PhRMA (1997) 1997 industry profile. Pharmaceutical Research and Manufacturers of America
20. Schwartzman D (1976) Innovation in the pharmaceutical industry. Johns Hopkins University Press, Baltimore
21. Scherer FM (1998) The size distribution of profits from innovation. Annales d'Economie et de Statistique
22. Scherer FM (1978) Technological maturity and waning economic growth. Arts and Science 1: 7-11
23. Suslow VY (1996) Measuring quality change in the market for anti-ulcer drugs. In: Helms RB (ed) Competitive strategies in the pharmaceutical industry. AEI Press, Washington
24. Sykes R (1997) The pharmaceutical industry in the new millennium: Capturing the scientific promise. Centre for Medicines Research International Publications, Carshalton, Surrey, UK
25. Towse A (1995) (ed), Industrial policy and the pharmaceutical industry. Office of Health Economics, London
26. U.S. House of Representatives (1995) Hearings before the Subcommittee on Health and the Environment
27. Wardell WW, Lasagna L (1975) Regulation and drug development. AEI Press, Washington